Use our account feature to register for a free CLI account. Your new account will allow you to bookmark and organize articles and research for easy reference later - making it simple to keep track of the research that's important to you!
Register / Sign in
Search Icon
Search Icon
Use our account feature to register for a free CLI account. Your new account will allow you to bookmark and organize articles and research for easy reference later - making it simple to keep track of the research that's important to you!
Register / Sign in
close-panel

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Get Notifications

Sign up to receive email updates from Charlotte Lozier Institute.

This field is for validation purposes and should be left unchanged.

Become A Defender of Life

Your donation helps us continue to provide world-class research in defense of life.

DONATE

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Maternal & Public HealthAbortion Drugs Fortune Journal of Health Sciences

Inducing Demand for Abortion in the Absence of Medical Necessity: Planned Parenthood and Abortion Drugs

Abstract

After nearly three decades of persistent decline in the U.S., the volume and rate of induced abortions turned unexpectedly upward in 2018. Given the discretionary preferential nature of the abortion decision, supply-induced demand (SID) is likely an important contributor to this abrupt change. We discuss the dominant provider (Planned Parenthood Federation of America) and abortion method (medical abortion), and the means by which they enhance demand. Their combined efforts and evolution have enabled the survival of abortion services even during three decades of contraction and the subsequent current period of growth.

Read Press Release

Read Complete Article

Latest Posts

October 6, 2026 A magnifying glass rests on three wooden blocks that spell out FDA, symbolizing a review of the REMS modification. A Critical Analysis of the FDA’s 2021 Mifepristone REMS Modification Rationale Review October 6, 2026 Ultrasound image showing the side profile of a human baby Inside The Government Decision That Opened Up Abortion Pill Floodgates October 6, 2026 A sign for the FDA featuring the agency’s logo and circular seals in front of a brick government building, where clinical guidance for mifepristone REMS is often determined. Unintended Consequences of the FDA’s 2021-2023 Risk Evaluation and Mitigation Strategy (REMS) Changes to Mifepristone

You Might Also Be Interested In

Abortion Reporting: Kentucky (2025)

October 5, 2026
Please login to bookmark Close

Abortion Reporting: Alabama (2025)

October 5, 2026
Please login to bookmark Close

Abortion Reporting: Virginia (2024)

October 5, 2026
Please login to bookmark Close

Become A Defender of Life

Your donation helps us continue to provide
world-class research in defense of life.

BECOME A PARTNER
cta-image